IDV vehicle
W911SR22D0009
ACQUISITION OF FDA APPROVED PRODUCT
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | W6QK ACC-APG |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN42 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $249.0M |
| Start date | Jan 3, 2022 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Dec 30, 2025 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 30, 2025 | P00006 | $0 | THIS CONTRACT WILL COMPLETE ADVANCED DEVELOPMENT OF THE MONOCLONAL ANTIBODY DRUG PRODUCT, G03-52-01, TO REGULATORY APPROVAL FOR PROPHYLAXIS (POST-EXPOSURE AND/OR PRE-EXPOSURE) TO BOTULINUM TOXIN. |
| Apr 14, 2025 | P00005 | $0 | THIS CONTRACT WILL COMPLETE ADVANCED DEVELOPMENT OF THE MONOCLONAL ANTIBODY DRUG PRODUCT, G03-52-01, TO REGULATORY APPROVAL FOR PROPHYLAXIS (POST-EXPOSURE AND/OR PRE-EXPOSURE) TO AEROSOLIZED BOTULINUM NEUROTOXIN A AND B SEROTYPES. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.